The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
December 2nd 2024
Ustekinumab-kfce is planned for launch in February 2025 according to a previous settlement and license agreement with Janssen.
November 27th 2024
November 26th 2024
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Younger Age Deemed Risk Factor of Flare in Patients Discontinuing Glucocorticoids
Patients with systemic lupus erythematosus who were younger in age or were serologically active yet clinically quiescent were more likely to have disease flare during glucocorticoid cessation.
COVID-19 Booster May Enhance T-cell Immune Response in Rituximab-Treated Patients With RA
While patients with rheumatoid arthritis on rituximab therapy have been reported to have insufficient serological responses to the COVID-19 vaccine, T cells, which protect against severe COVID-19, may be elevated after a third dose.
Efficacy and Safety of Tofacitinib Not Impacted by Dose-Switching
While patients with rheumatoid arthritis may benefit from either increasing or decreasing their dosage of tofacitinib, post-hoc analysis indicates that safety and efficacy of the medication is not impacted by these changes.
Autoantibody Testing Detects SLE and Lupus Nephritis
“Although many different autoantibodies have been investigated in SLE, only a limited number of autoantibodies are being used in clinical practice,” investigators stated. “Due to these limitations, there has been great interest in the discovery of new autoantibodies that can be used in clinical practice.”
Risk Factors Identified for Atherosclerosis and Cardiovascular Events in Women With SLE
Women with systemic lupus erythematosus are more likely to have accelerated progression of atherosclerosis. Recognizing the risk factors, such as larger waist circumference and higher fasting glucose levels, may be an important step in preventing this condition.
Home-Based Exercise Program Improves Quality of Life for Patients With Juvenile Dermatomyositis
“Preliminary evidence has suggested that an exercise training could be effective in improving physical function and quality of life in juvenile dermatomyositis, without exacerbating the disease,” investigators stated.